• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

    10/22/24 4:05:00 PM ET
    $ALLO
    $ARTV
    $CDXS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLO alert in real time by email

    SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allogene Therapeutics (NASDAQ:ALLO), a pioneering clinical-stage company advancing CAR T-cell therapies.

    "We are honored to welcome Alison to the Artiva Board of Directors. Her decades of executive experience in manufacturing and technical operations across modalities, specifically in allogenic cell therapies, will bring an important perspective to our team as we advance our pipeline in the clinic," said Fred Aslan, M.D., CEO of Artiva. "In parallel to our efforts to evaluate the efficacy and safety of AlloNK®, we believe the extensive history of our manufacturing process sets us apart from our allogeneic cell therapy peers, potentially accelerating our path to bring this experimental therapy to patients."

    Dr. Moore added, "I have been impressed with the scalability and robustness of AlloNK®'s manufacturing process at this stage of development. Built on a decade of leadership, the lack of genetic engineering simplifies the manufacturing process, and the clinical experience to date suggests this therapy offers a compelling approach to depleting B cells and potentially addressing the unmet need for patients with devastating autoimmune diseases and cancers. I am excited to join the board at this critical point in Artiva's evolution to help realize the full potential of AlloNK® for the treatment of autoimmune disease and cancer."

    Prior to Codexis and Allogene, Dr. Moore spent 20 years at Amgen, most recently as Senior Vice President of Process Development, with leadership roles in Supply Chain and Manufacturing. Before joining Amgen, she held positions at Genentech in chemistry, manufacturing and regulatory affairs. Dr. Moore holds a bachelor's degree in pharmacology with Honors and a Ph.D. in Cell Biology from Manchester University, England.

    About Artiva Biotherapeutics

    Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva's lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva's pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell's NK cell manufacturing technology and programs. 

    Artiva is headquartered in San Diego, California. For more information, please visit https://www.artivabio.com/.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements.  Such forward-looking statements include, without limitation, statements regarding the potential benefits, accessibility, effectiveness and safety of AlloNK® and Artiva's manufacturing strategy.  These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company's actual results to differ from current expectations are discussed in the Company's filings with the Securities and Exchange Commission (the "SEC"), including the section titled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contacts

    Investors: Neha Krishnamohan, Artiva Biotherapeutics, [email protected]

    Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., [email protected], +1.858.344.8091



    Primary Logo

    Get the next $ALLO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Q&A

    New
    • What qualifications does Dr. Alison Moore bring to the Artiva Biotherapeutics board?

      Dr. Alison Moore has over 25 years of experience in the biotechnology and pharmaceutical industry, specifically in cell therapy manufacturing. She has served as CTO at Codexis and formerly at Allogene Therapeutics and has also held leadership roles at Amgen and Genentech.

    • What is the AlloNK™ therapy being developed by Artiva Biotherapeutics?

      AlloNK™ is an allogeneic, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the effect of monoclonal antibodies in driving B-cell depletion. It is currently undergoing clinical trials for autoimmune diseases like systemic lupus erythematosus.

    • What is the mission of Artiva Biotherapeutics and what does their product pipeline include?

      Artiva Biotherapeutics focuses on developing safe and accessible cell therapies for autoimmune diseases and cancers, with their lead program, AlloNK™, being a significant part of their pipeline which may include CAR-NK candidates for various cancers.

    • What distinguishes Artiva's AlloNK™ manufacturing process from that of its competitors?

      Artiva’s manufacturing process for AlloNK™ is considered scalable and robust, reportedly simplified due to the lack of genetic engineering. This manufacturing strategy aims to accelerate their development path compared to competitors in the allogeneic cell therapy space.

    • What are Dr. Moore's thoughts on joining the Artiva Biotherapeutics board and the AlloNK™ therapy?

      Alison Moore expressed excitement to join Artiva at a crucial time, emphasizing the potential of AlloNK™ to address unmet needs in treating patients with autoimmune diseases and cancers due to its simplified manufacturing and demonstrated clinical efficacy.

    Recent Analyst Ratings for
    $ALLO
    $ARTV
    $CDXS

    CompanyDatePrice TargetRatingAnalyst
    Artiva Biotherapeutics Inc.
    $ARTV
    6/11/2025$12.00Buy
    H.C. Wainwright
    Allogene Therapeutics Inc.
    $ALLO
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Allogene Therapeutics Inc.
    $ALLO
    3/14/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Artiva Biotherapeutics Inc.
    $ARTV
    12/30/2024$20.00Buy
    H.C. Wainwright
    Codexis Inc.
    $CDXS
    8/19/2024Buy → Hold
    The Benchmark Company
    Artiva Biotherapeutics Inc.
    $ARTV
    8/13/2024$21.00Buy
    Jefferies
    Artiva Biotherapeutics Inc.
    $ARTV
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    Artiva Biotherapeutics Inc.
    $ARTV
    8/13/2024Buy
    TD Cowen
    More analyst ratings

    $ALLO
    $ARTV
    $CDXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $239,000 worth of shares (100,000 units at $2.39) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      7/1/25 4:05:08 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • SEC Form 4 filed by Director Ra Capital Management, L.P.

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      6/26/25 4:51:19 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Moore Alison

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      6/26/25 4:30:22 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    $ARTV
    $CDXS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Allogene Therapeutics Inc.

      SCHEDULE 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)

      7/16/25 6:02:33 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      6/25/25 4:02:37 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)

      6/23/25 4:28:23 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    $ARTV
    $CDXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Artiva Biotherapeutics with a new price target

      H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00

      6/11/25 7:52:47 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene downgraded by Citizens JMP

      Citizens JMP downgraded Allogene from Mkt Outperform to Mkt Perform

      5/14/25 8:54:15 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00

      3/14/25 7:12:11 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    $ARTV
    $CDXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $239,000 worth of shares (100,000 units at $2.39) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      7/1/25 4:05:08 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $560,009 worth of shares (250,000 units at $2.24) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      6/16/25 4:59:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $5,487,000 worth of shares (2,325,000 units at $2.36) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      5/28/25 4:05:23 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $ALLO
    $ARTV
    $CDXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair

      ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. "We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magni

      6/23/25 8:45:00 PM ET
      $ARTV
      $CTNM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

      Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response RateFour of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic PlatformPhase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Effic

      6/1/25 10:45:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

      SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT. Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the "Investor

      5/28/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    $ARTV
    $CDXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

      IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

      5/8/25 8:00:00 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

      SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

      4/8/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Codexis Appoints Cynthia Collins to Board of Directors

      REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company's Board of Directors. "I am thrilled to welcome Cindy to our Board," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "She has been at the forefront of innovation across multiple therapeutic modalities and brings a wealth of knowledge about the CDMO landscape. I look forward to her valuable guidance as we continue expanding the commercial footprint of our ECO Synthesis toolbox." Ms. Collins added,

      4/1/25 7:00:00 AM ET
      $CDXS
      Major Chemicals
      Industrials

    $ALLO
    $ARTV
    $CDXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

      SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      11/14/24 4:56:18 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Allogene Therapeutics Inc.

      SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

      11/12/24 1:26:25 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Allogene Therapeutics Inc.

      SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)

      11/4/24 10:57:36 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    $ARTV
    $CDXS
    Financials

    Live finance-specific insights

    See more
    • Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

       Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demon

      5/22/25 7:00:00 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Reports First Quarter 2025 Financial Results

      Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "Codexis finished the first quarter with $60 million in cash, which remains on track to fund the company through cash flo

      5/14/25 4:05:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

      Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from InvestigatorsLymphodepletion Selection and Futility Analysis Shifted to 1H 2026 in Part Due to Site-Related Factors that Impacted Expected Pace of Screening Immediately Following Site ActivationOver 250 Patients Consented for MRD Screening to Date, with Nearly Half in the Last Three Months and Awaiting Completion of 1L Treatment as Earliest Activated Sites Build MomentumInternational Expansion of ALPHA3 Trial to Begin with Site Activations in Canada in Q2 2025 Phase 1 RESOLUTION Trial with A

      5/13/25 4:05:00 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care